Background -The neutrophil is a potent contributor to pulmonary destruction in cystic fibrosis. Since eosinophils also possess destructive potential the involvement of eosinophils in cystic fibrosis has been investigated. Methods -Eosinophil numbers and levels of eosinophil cationic protein (ECP), a marker of eosinophil activation, were determined in the serum of 42 patients with cystic fibrosis and in the sputum of 10 of them. To determine neutrophil activation levels of myeloperoxidase (MPO) were also measured. Results -In cystic fibrosis increased serum levels of ECP were detected compared with healthy non-atopic subjects. Serum ECP levels were not related to the peripheral blood eosinophil count. A strong correlation with ECP concentrations in sputum indicated that the level of ECP in serum was representative of its pulmonary level. Levels of MPO were also increased in cystic fibrosis. A strong correlation was found between MPO and pulmonary function. In addition, ECP was related to arterial oxygen and carbon dioxide tensions. Antibiotic treatment reduced neutrophil activation without effect on ECP levels. Conclusions -Until now Pseudomonas aeruginosa and neutrophils were held to be primarily responsible for progressive tissue damage in cystic fibrosis. The results of this study suggest that eosinophils might also participate in such pulmonary destruction. (Thorax 1994;49:496-499) Allergy and Immunology Unit
D Y Koller, M Gotz, I Eichler, R Urbanek Abstract Background -The neutrophil is a potent contributor to pulmonary destruction in cystic fibrosis. Since eosinophils also possess destructive potential the involvement of eosinophils in cystic fibrosis has been investigated. Methods -Eosinophil numbers and levels of eosinophil cationic protein (ECP), a marker of eosinophil activation, were determined in the serum of 42 patients with cystic fibrosis and in the sputum of 10 of them. To determine neutrophil activation levels of myeloperoxidase (MPO) were also measured. Results -In cystic fibrosis increased serum levels of ECP were detected compared with healthy non-atopic subjects. Serum ECP levels were not related to the peripheral blood eosinophil count. A strong correlation with ECP concentrations in sputum indicated that the level of ECP in serum was representative of its pulmonary level. Levels of MPO were also increased in cystic fibrosis. A To determine the effect of antibiotic treatment on granulocyte activation, eight patients were studied before and after 2-3 weeks of treatment with aminoglycoside and ceftazidime. As a control group 30 healthy nonatopic subjects (16 men and 14 women) of mean age 13-4 (range 4-32) years were also studied.
Parental or the patient's agreement to blood sampling was obtained in all cases and blood was obtained at routine sampling for clinical evaluation.
CYSTIC FIBROSIS SCORE AND PULMONARY

FUNCTION
The clinical severity of cystic fibrosis was assessed by the Shwachman-Kulczycki score.14 Pulmonary function was determined by whole body plethysmography (Masterlab; Jaeger, Germany) and expressed in relation to predicted values.'5 BLOOD AND SPUTUM SAMPLES Blood eosinophil and neutrophil counts were determined by automated counting (Sysmex NE-5500; Muller, Austria), with a coefficient of variation for eosinophils and neutrophils of 7-0% and 4-8% respectively. Sputum samples (1 g) were extracted immediately to avoid cell damage in 1 ml phosphate buffered saline and vortex mixed for 30 seconds. Extracts were centrifuged at 3000 rpm for 20 minutes at 4°C. Approximately 80% of sputum samples yielded clear supernatants after this procedure. In the remaining 20% the extremely viscous mucus did not separate initially into two phases and the process was repeated.
Concentrations of ECP and MPO in serum and sputum supernatant were determined by double antibody radioimmunoassays (Pharmacia Diagnostics AB, Sweden 153-4) cells/jl) in control subjects. In the group with cystic fibrosis only six patients showed elevated eosinophil numbers and no differences occurred between groups. Increased serum levels of ECP were detected in the group with cystic fibrosis (range 13-2-141 8 jg/l; mean 59-7 (28-99) pg/l) compared with the control group (range 3 5-15 9 jg/l; mean 8-1 (2-85) jg/l) (fig 1) .
In sputum from patients with cystic fibrosis ECP levels ranged from 1 0 to 1-45 mg/l (mean 1 2 (0 17) mg/l), and were strongly correlated with serum levels of ECP (fig 2) . No relation occurred between ECP levels, the blood eosinophil count, and age in the patients with cystic fibrosis. Serum concentrations of ECP were related to arterial Pco2 and Po2, and the severity of cystic fibrosis ( (fig 3) .
Discussion
The increased serum and high sputum ECP levels in patients with cystic fibrosis suggest activation of eosinophils. 22 in which the destructive role for eosinophils is assumed. Although these associations do not prove a causal relation between eosinophils and pulmonary destruction in cystic fibrosis, they suggest that eosinophils may be doing more harm than good. The high concentrations of ECP in sputum support this hypothesis since concentrations are higher than those needed for tissue injury in vitro. In contrast to asthma, increased serum ECP levels occurred with a normal peripheral blood eosinophil count in most of the patients with cystic fibrosis. Eosinophils in cystic fibrosis may have an increased propensity to release their granule proteins. They can be activated by several exogenous and endogenous stimuli,3 but Ps aeruginosa infection is probably not a stimulus as patients with and without colonisation had similar serum ECP concentrations. Endogenous factors may therefore be responsible for eosinophil activation. Such factors include interleukin 3 and 5, and tumour necrosis factor a, which is increased in cystic fibrosis,23 and possibly by IgE and IgG mediated mechanisms acting with complement via CR1 and CR3 receptors.
The importance of neutrophils in tissue damage in cystic fibrosis has been demonstrated. 24 The neutrophil MPO-H2 2-halide enzyme system produce hypochlorous acid and chlorinated amine compounds capable of killing various target cells.' The increased serum and sputum levels of MPO in our patients are analogous to previous findings,'2 and support a role in lung injury. It is unknown to what extent neutrophils and eosinophils are beneficial in Ps aeruginosa infection in cystic fibrosis. The failure of antibiotic treatment to reduce ECP and MPO to normal levels, although the latter decreased significantly, indicates a potential for injury.
Additional forms of treatment in cystic fibrosis need to be evaluated with the aim of reducing eosinophil and neutrophil activation.
Previously Ps aeruginosa and neutrophil products were considered to be responsible for progressive lung damage in cystic fibrosis. Our results suggest the participation also by eosinophils in continuing pulmonary destruction in cystic fibrosis. 
